{"id":"ak112-high-dose","safety":{"commonSideEffects":[{"rate":null,"effect":"Immune-related adverse events (irAEs)"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"AK112 functions as a bispecific monoclonal antibody designed to bind both PD-1 and CTLA-4, two key immune checkpoint molecules. By engaging both pathways simultaneously, the drug aims to provide enhanced T-cell activation and proliferation compared to single-checkpoint inhibitors, potentially overcoming resistance mechanisms in cancer immunotherapy.","oneSentence":"AK112 is a bispecific antibody that simultaneously engages PD-1 on immune cells and CTLA-4 to enhance anti-tumor immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:21:21.375Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (Phase 2 evaluation)"}]},"trialDetails":[{"nctId":"NCT07412262","phase":"PHASE2","title":"A Prospective, Single-Arm, Multicenter, Phase II Clinical Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer With Acquired Resistance to Immunotherapy and High YAP Protein Expression","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Association of Clinical Trials","startDate":"2026-03-31","conditions":"Non-Small Cell Lung Cancer","enrollment":32},{"nctId":"NCT07064902","phase":"PHASE2","title":"Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-08-01","conditions":"Nasopharyngeal Carcinoma (NPC)","enrollment":48},{"nctId":"NCT06686030","phase":"PHASE2","title":"Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer","status":"RECRUITING","sponsor":"Akeso","startDate":"2025-02-17","conditions":"Platinum-sensitive Ovarian Cancer","enrollment":150},{"nctId":"NCT06930573","phase":"PHASE4","title":"A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2024-12-04","conditions":"HCC","enrollment":30},{"nctId":"NCT06593548","phase":"PHASE2","title":"Lvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-11-01","conditions":"CRC, MSS, Metastatic Cancer","enrollment":36},{"nctId":"NCT04999605","phase":"PHASE1, PHASE2","title":"A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer","status":"TERMINATED","sponsor":"Akeso","startDate":"2021-06-24","conditions":"Ovarian Neoplasms, Recurrent Ovarian Carcinoma, Relapsed Ovarian Cancer","enrollment":8}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AK112 high dose","genericName":"AK112 high dose","companyName":"Akeso","companyId":"akeso","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AK112 is a bispecific antibody that simultaneously engages PD-1 on immune cells and CTLA-4 to enhance anti-tumor immune responses. Used for Advanced or metastatic solid tumors (Phase 2 evaluation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}